. MRD testing allows clinicians to detect small number of malignant cells persisting post-treatment and aids in monitoring treatment response and prognosis. Growing demand for personalized medicine has prompted healthcare professionals to incorporate MRD testing during diagnosis and treatment of various chronic conditions.

The global minimal residual disease testing market is estimated to be valued at US$ 4.97 Bn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 to 2031.

Key Takeaways
Key players operating in the minimal residual disease testing are Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc. These players are focusing on launching innovative MRD testing solutions and engaging in strategic partnerships and acquisitions to cement their market position.

The rising incidence of chronic diseases provides significant growth opportunities for market players. According to WHO, cancer burden is expected to grow by over 70% in the next two decades. Hence, demand for MRD testing solutions to monitor treatment response and identify early relapse is anticipated to rise sharply.

Key players are strategically expanding their global footprint by establishing their presence in emerging markets. For instance, Sysmex Inostics expanded its distribution network across Asia and Europe. Bio-Rad Laboratories acquired Excilone to strengthen its MRD testing portfolio and presence in France.

Market drivers:
– Rising prevalence of chronic diseases like blood cancer, lymphoma, leukemia is boosting demand for MRD testing to monitor response to treatment and relapse.
– Growing focus on personalized medicine is prompting incorporation of MRD testing during diagnosis and treatment to offer targeted therapy.

Market restraints:
– High costs associated with MRD testing procedures limiting widespread adoption.
– Lack of skilled professionals and standard protocols hampering market growth.

Segment Analysis
The Minimal Residual Disease Testing Market Size is dominated by flow cytometry segment due to its wide usage in diagnosing various blood cancers such as acute lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, etc. Flow cytometry allows detection of rare tumor cells in patient’s blood/bone marrow samples with high sensitivity and specificity. It is considered as standard technology for MRD testing in leukemia patients during and post-treatment to check treatment response and make decisions regarding further treatment plans.

Global Analysis
North America is the fastest growing as well as dominating regional market for minimal residual disease testing. Large presence of leading market players, growing prevalence of cancer, increasing awareness about MRD testing, favorable reimbursement policies, and rising adoption of innovative technologies drive the North America MRD testing market. Asia Pacific is expected to witness highest CAGR during the forecast period due to improving healthcare infrastructure, rising healthcare spending, growing cancer incidence, and increasing focus of global players on expanding their presence in Asia Pacific countries.

Get more insights on This Topic- Minimal Residual Disease Testing Market

According to research report the global minimal residual disease testing market is projected to reach USD 2.3 Billion by 2027, at a CAGR of 14.0%. Increasing prevalence of cancer and hematological malignancies, rising initiatives undertaken by government bodies to create awareness about cancer, and increasing collaborations are factors driving the growth of the global minimal residual disease testing market. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the minimal residual disease testing market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215386038

The PCR segment accounted for the largest share of the minimal residual disease testing market, by technology segment, in 2021

Based on technology, the minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS). The polymerase chain reaction technology segment accounted for the largest share in 2021. The large share of this segment is due to the device being easy to use, being easily available with relative sensitivity and cost efficiency.

Hematological Malignancies segment to register the highest growth rate during the forecast period

Based on applications, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies segment accounted for the largest share primarily due to factors such as the increasing incidence of leukemia and lymphoma and the need to continuously monitor the patients with these diseases.

The hospitals & specialty clinics accounted for the largest share of the minimal residual disease testing market, by end user segment, in 2021

Based on end users, the minimal residual disease testing market has been segmented into hospitals & specialty clinics, diagnostic laboratories, academic & research institutes, and other end users. In 2021, the hospitals & specialty clinics segment accounted for the largest share of this market, due to availability of advanced diagnostic devices with skilled and professional healthcare workforce.

North America is the largest regional market for minimal residual disease testing market

The global minimal residual disease testing market has been segmented into four major regions—North America, Europe, the Asia Pacific, Latin America and Middle East and Africa. North America accounted for the largest share of the minimal residual disease testing market. The large share of this regional segment can be attributed to the growing incidence of hematological malignancies which include leukemia and lymphoma, well-developed healthcare systems in the US and Canada, the presence of many leading clinical laboratories across nation, and the easy availability of advanced diagnostic instruments.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=215386038

The major players operating in this market are Labcorp Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland),  Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Arup Laboratories Inc. (US), Bio-Rad Laboratories, Inc. (US), Cergentis B.V. (Netherlands), Molecular MD (ICON plc) (Ireland), Invivoscribe, Inc. (US), Mission Bio, Inc. (US), Natera, Inc. (US), Opko Health, Inc. (US), Quest Diagnostics (US), and Genetron Health (China), among others.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

According to research report the global minimal residual disease testing market is projected to reach $2.3 billion by 2027, growing at a CAGR of 14.0% from 2022. Key factors driving this market expansion include the rising prevalence of cancer and hematological malignancies, increasing government initiatives to raise awareness about cancer, and growing collaborations among stakeholders. Emerging economies like China, Japan, and India present lucrative opportunities for market players.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215386038

Driver: Rising incidence of hematological malignancies

Over the years, the incidence of hematologic cancer has increased significantly, which includes leukemia and lymphoma. According to the Leukemia & Lymphoma Society 2020-2021, an estimated 1,519,907 people in the US are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPNs). Also, the rising geriatric population across the globe is also a key factor supporting the increasing incidence of hematologic malignancies, as this population segment is more prone to various chronic diseases. Such cancer patients require continuous monitoring of disease during treatment. Also, the monitoring of minimal residual diseases (MRD) has become a routine clinical practice post-cancer treatment. As a result, the preference for minimal residual disease testing will likely rise in the forecast period, proportional to the growth in cancer prevalence.

Segmentation Insights:

By Technology:
– The polymerase chain reaction (PCR) segment held the largest share in 2021 due to its ease of use, availability, relative sensitivity, and cost-efficiency.

By Application:
– The hematological malignancies segment is expected to register the highest growth rate during the forecast period, primarily driven by the increasing incidence of leukemia and lymphoma, necessitating continuous patient monitoring.

By End-User:
– In 2021, the hospitals and specialty clinics segment accounted for the largest share owing to the availability of advanced diagnostic devices and skilled healthcare professionals.

Regional Analysis:
– North America dominated the MRD testing market, attributed to the growing incidence of hematological malignancies, well-developed healthcare systems, the presence of leading clinical laboratories, and easy access to advanced diagnostic instruments.

Key Players:
Labcorp Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Sysmex Corporation, NeoGenomics Laboratories, Inc., Adaptive Biotechnologies Corporation, ArcherDX, Inc., Asuragen Inc., Arup Laboratories Inc., Bio-Rad Laboratories, Inc., Cergentis B.V., Molecular MD (ICON plc), Invivoscribe, Inc., Mission Bio, Inc., Natera, Inc., Opko Health, Inc., Quest Diagnostics, and Genetron Health, among others.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=215386038

The report provides a comprehensive analysis of the MRD testing market, including market size, growth projections, segmentation insights, regional dynamics, and competitive landscape. It offers valuable insights for companies operating in this space and those seeking to enter or expand their presence in the MRD testing market.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

© 2024 Crivva - Business Promotion. All rights reserved.